<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> have antibodies against <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> antigens </plain></SENT>
<SENT sid="1" pm="."><plain>Characterising the antibody repertoire may provide insights into aberrant cellular mechanisms in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development, ultimately leading to novel diagnostic or therapeutic targets </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to characterise the antibody profiles in patients whose symptoms warranted colonoscopy, to see if there was a difference in patients with and without <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Patients were recruited from a colonoscopy clinic </plain></SENT>
<SENT sid="4" pm="."><plain>Individual serum samples from 43 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and 40 patients with no <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> on colonoscopy were profiled on a 37 830 clone recombinant human protein array </plain></SENT>
<SENT sid="5" pm="."><plain>Antigen expression was evaluated by quantitative reverse transcription-PCR and by immunohistochemistry on tissue microarrays </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Using a sex- and age-matched training set, 18 antigens associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and 4 associated with the absence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (p&lt;0.05) were identified and confirmed </plain></SENT>
<SENT sid="7" pm="."><plain>To investigate the mechanisms triggering antibody responses to these antigens, antigen expression was examined in <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal mucosa and colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> of the same patients </plain></SENT>
<SENT sid="8" pm="."><plain>The identified antigens showed cellular accumulation (p53), aberrant cellular expression (high mobility group B1 (HMGB1)) and overexpression (tripartite motif-containing 28 (TRIM28), p53, HMGB1, transcription factor 3 (TCF3), longevity assurance gene homologue 5 (LASS5) and zinc finger protein 346 (ZNF346)) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissue compared with <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal mucosa </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: It is demonstrated for the first time that screening high-density protein arrays identifies unique antibody profiles that discriminate between symptomatic patients with and without <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>The differential expression of identified antigens suggests their involvement in aberrant cellular mechanisms in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>